Notable’s Post

A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases. This study is the first to show comprehensively the disparities in the AE profiles of palbociclib and abemaciclib. The findings highlight the importance of considering these differences when selecting a suitable CDK4/6 inhibitor to ensure safe and favourable outcomes for patients with breast cancer. Derek Stewart European Society of Clinical Pharmacy (ESCP) Yolande Hanssens Vibhu Paudyal Shusen Sun Filipa Alves da Costa Matej Štuhec PharmD PhD Univ.-Prof. Dr. Anita Weidmann #pharmacy #pharmacists #pharmacylife #clinicalpharmacy #pharmaceuticalcare #pharmacycollege #pharmacystudents #pharmacytechnicians https://lnkd.in/dGgT65rZ

Our congress report from EHA2024 is now available! Follow the link below to download the report from memoinoncology.com #haematology #hematology #EHA2024 #medicaleducation #cancerresearch

The new IQVIA “HOPE” report (Hematologic Cancer Opportunities for Patient Equality) forecasts a 55% increase in hematological cancer cases by 2050, from 1.3 million in 2022 to 2.03 million. It analyzes therapy availability, regulatory approvals, reimbursement, and drug usage for hematological malignancies in selected countries. The report compares these trends with solid tumors, discusses the prevalence of combination therapies, and explores potential trend drivers and challenges for hematology drugs. It concludes with a call for policy action. Read the report here: https://bit.ly/4bZ2kAd #Hematology #HealthEquity #GlobalHealth

November is #LungCancer Awareness month 🫁 📣 Check out this NEW interview from #ESMO2023 | #MARIPOSA-2: #amivantamab + #chemo (± #lazertinib) vs #chemo in #EGFR-mutated #NSCLC post-#osimertinib 🎥 Antonio Passaro, MD, PhD, IEO European Institute of Oncology, discusses the Phase III #MARIPOSA-2 (NCT04988295) trial, exploring the effectiveness of #amivantamab (ami) in combination with #carboplatin-pemetrexed (chemo) with or without #lazertinib (laz) in patients with #EGFR-mutated advanced #nonsmallcelllungcancer (#NSCLC) who had experienced disease progression on #osimertinib ⭐ The trial demonstrated significant improvements in progression-free survival (PFS), objective response rate (ORR), and intracranial PFS for both ami-chemo and ami-laz-chemo compared to chemo alone ⭐ The interim overall-survival (OS) data showed promising trends. Hematologic, #EGFR, and MET-related adverse events were observed in the ami-containing arms, with lower #hematologic #toxicity in the ami-#chemo arm ⭐ Longer-term follow-up is needed to assess the impact of regimen modifications on #safety and #efficacy These findings suggest that ami-chemo and ami-laz-chemo could become a new standard of care for #EGFR-mutated advanced #NSCLC patients who progressed on #osimertinib 🔦 Give it a watch to learn more 👉 https://lnkd.in/eMnRiFC5 #Oncology ESMO - European Society for Medical Oncology #LungCancerAwarenessMonth #LCsm

🌟 𝐂𝐚𝐥𝐪𝐮𝐞𝐧𝐜𝐞 𝐏𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐂𝐨𝐧𝐟𝐢𝐫𝐦𝐞𝐝: 𝐀𝐬𝐭𝐫𝐚𝐙𝐞𝐧𝐞𝐜𝐚 𝐒𝐡𝐚𝐫𝐞𝐬 𝐃𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐌𝐚𝐧𝐭𝐥𝐞 𝐂𝐞𝐥𝐥 𝐋𝐲𝐦𝐩𝐡𝐨𝐦𝐚 𝐃𝐚𝐭𝐚 📈 𝗜𝗻 𝗝𝘂𝗻𝗲 𝟮𝟬𝟮𝟰, AstraZeneca has provided data to support its claim that its #blood #cancer medication #Calquence, when combined with #chemotherapy and #immunotherapy, is effective in treating patients with mantle #celllymphoma (MCL) who had not had prior treatment, as shown six weeks ago in an interim analysis of a phase 3 trial. The ECHO research found that a 27% lower risk of disease progression or mortality was associated with the addition of Calquence to the bendamustine and rituximab (BR) combination. At the European Haematology Association (EHA) Congress in Madrid, AstraZeneca revealed the trial results, saying that the amount is both statistically and clinically significant. A median progression-free survival (PFS) of 66.4 months was achieved with the Calquence combo in the research, which involved 𝟮𝟵𝟵 patients in each arm who were 65 years of age or older, as opposed to 𝟰𝟵.𝟲 months with BR alone. Furthermore, Calquence demonstrated a positive #trend in overall survival (OS), a first for a #BTK #inhibitor. AstraZeneca emphasized that OS will continue to be evaluated as a secondary endpoint in the ongoing trial and that the data has not yet reached maturity. 𝗟𝗼𝗼𝗸 𝗮𝘁 𝗼𝘂𝗿 𝗖𝗼𝗿𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁 👉: https://bit.ly/3WJQN2D #Calquence #MantleCellLymphoma #CancerResearch #Oncology #ClinicalData #CancerTreatment #MedicalBreakthrough #Hematology #InnovativeTherapy #prophecymarketinsights

Insightful report on Hematologic Cancer with insights to therapy availability and reimbursement in a range of countries

NEW from #ASCO2023 | SONIA: optimal #CDK4/6 inhibitor position in #HR+, #HER2- advanced BC 🎥 Phase III SONIA (NCT03425838) trial evaluating the #efficacy, #safety, and #cost-effectiveness of #CDK4/6 #inhibitors (CDK4/6i) combined with #endocrine therapy (ET) in HR+, #HER2- advanced #breastcancer (ABC) patients with no prior #ABC treatment 💡 ⭐ Patients were randomized to receive either #CDK4/6i + ET as first-line treatment followed by #fulvestrant (F) on progression (strategy A) or ET alone as first-line followed by F + #CDK4/6i on progression (strategy B) ⭐ After a median follow-up of 37.7 months, there was no statistically significant difference in progression-free survival (PFS2) between the two strategies ⭐ Strategy A prolonged time on CDK4/6i by 16.4 months but also increased #toxicity and costs ⭐ Second-line use of CDK4/6i may be a preferred option for most patients with HR+, HER2- ABC Give it a watch to learn more 👉 https://lnkd.in/druhKTGa #Oncology #BCsm #AdvancedBreastCancer

Exciting News in Oncology! #Osimertinib General Pharmaceuticals Ltd introduces- #Osimertinib ,which is revolutionizing cancer treatment, offering targeted therapy for certain lung cancers. #Osmigen(Osimertinib 80mg tablets) Treatment with osimertinib after surgery significantly lowered the risk of death in adults with completely resected EGFR-mutated stage IB, II, or IIIA non–small cell lung cancer (NSCLC), according to the findings of the international ADAURA study. Osimertinib is a third-generation, central nervous system–active EGFR tyrosine kinase inhibitor and is the first targeted agent to be approved by the U.S. Food and Drug Administration as an adjuvant treatment for patients with resected stage IB to IIIA EGFR-mutated NSCLC. The research was presented at the 2023 ASCO Annual Meeting by Roy S. Herbst, MD, PhD, and colleagues (Abstract LBA3). #Reference : https://lnkd.in/gbnBW4vz #Available_for_Export ! 👉 For any Order please contact - ekram.imd@generalpharma.com WhatsApp: +8801844093150 #gpl #imd #export #ordernow #osmigen

📢 AstraZeneca's CALQUENCE® Could Significantly Improve Leukemia Survival Big news hits in the fight against chronic lymphocytic leukemia (CLL)! Interim results from the AMPLIFY Phase III trial reveal that the combination of CALQUENCE® (acalabrutinib) and venetoclax, with or without obinutuzumab, has shown significant improvements in progression-free survival (PFS) for previously untreated CLL patients. This is remarkable progress for those battling this chronic disease🩺 Not only is the PFS improved, but there is also a positive trend in overall survival (OS), although the data is not yet fully mature. What's particularly beneficial is the fixed-duration approach of the CALQUENCE combination. This method allows for treatment breaks, reducing long-term adverse effects and the risk of drug resistance, thereby improving the quality of life for patients.The safety profile of the combination remains consistent with individual medications, without new safety concerns and low cardiac toxicity rates ✅📉 #AstraZeneca #Oncology #LeukemiaTreatment #CLL #MedicalInnovation #ClinicalResearch #ClinicalTrials #LifeScience #ElixirAssociates #StaffingPartner

With FLAURAishing new frontline combination therapies for EGFR+ mNSCLC yet incomplete data—What to do NOW in clinic? Dr. Balazs Halmos and I share our thoughts in an editorial for American Society of Clinical Oncology (ASCO) Daily News!